| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.05▼ | 1.05▼ | 1.04▲ | 1.01▲ | 0.92▲ |
| MA10 | 1.01▲ | 1.01▲ | 1.01▲ | 0.99▲ | 1.03▲ |
| MA20 | 1.01▲ | 1.00▲ | 1.00▲ | 0.92▲ | 1.11▼ |
| MA50 | 0.99▲ | 0.99▲ | 0.96▲ | 1.04▲ | 1.13▼ |
| MA100 | 0.95▲ | 0.93▲ | 0.92▲ | 1.15▼ | 4.53▼ |
| MA200 | 0.92▲ | 1.00▲ | 1.04▲ | 1.17▼ | 172,757.69▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.009▲ | 0.008▲ | 0.006▲ | 0.023▲ | 1.601▲ |
| RSI | 58.124▲ | 57.937▲ | 57.965▲ | 55.652▲ | 23.642▼ |
| STOCH | 59.222 | 59.105 | 45.014 | 64.736 | 27.219 |
| WILL %R | -43.333 | -43.333 | -43.333 | -22.764▲ | -50.678 |
| CCI | 69.737 | 69.607 | 90.475 | 124.481▲ | -16.887 |
|
Wednesday, February 18, 2026 06:25 AM
Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for ...
|
|
Wednesday, February 18, 2026 04:17 AM
Nearly 60–70% of SCLC patients present with extensive-stage disease at diagnosis. Despite the availability of approved second-line agents, real-world data indicate that only 40% receive second-line ...
|
|
Tuesday, February 03, 2026 05:00 AM
TARPON SPRINGS, Fla., February 3, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 04/03/26 | 1.09 | 1.09 | 1.045 | 1.045 | 74,776 |
| 03/03/26 | 0.99 | 1.1201 | 0.9501 | 1.04 | 217,270 |
| 02/03/26 | 0.97 | 0.9999 | 0.97 | 0.995 | 60,873 |
| 27/02/26 | 1.00 | 1.02 | 0.97 | 0.97 | 69,803 |
| 26/02/26 | 1.03 | 1.0389 | 0.9648 | 0.995 | 62,765 |
| 25/02/26 | 0.9499 | 1.03 | 0.93 | 0.9999 | 113,169 |
| 24/02/26 | 0.9353 | 0.975 | 0.90 | 0.95 | 135,572 |
| 23/02/26 | 0.95 | 0.999 | 0.9066 | 0.9423 | 0 |
| 20/02/26 | 1.05 | 1.075 | 0.92 | 0.922 | 256,713 |
| 19/02/26 | 0.9006 | 1.09 | 0.9006 | 1.05 | 296,165 |
|
|
||||
|
|
||||
|
|